{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:43:38Z","timestamp":1748587418388,"version":"3.40.4"},"reference-count":13,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Dermatol"],"abstract":"<jats:p>Introduction: Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). To our knowledge, there have been no reported cases of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with dalbavancin and oritavancin. Patient Presentation: A woman in her 20s presented with a right thumb abscess and cellulitis that failed to respond to several courses of oral antibiotics, resulting in recurrent emergency room visits over 3 weeks. Approximately 1 month after the initial skin infection, magnetic resonance imaging revealed osteomyelitis of the right thumb. She was treated with a single dose of oritavancin followed by two weekly doses of dalbavancin, which successfully resolved the infection. However, she subsequently developed fever and a rash consistent with DRESS syndrome, likely triggered by oritavancin or dalbavancin. Given the prolonged half-life of these medications, she required treatment with high-dose steroids for an extended duration. Conclusion: Dalbavancin and oritavancin are second-generation lipoglycopeptide antibiotics that provide coverage for gram-positive organisms, including MRSA. They are approved for the treatment of acute bacterial skin and skin structure infections and are used off-label for bacteremia, endocarditis, and osteomyelitis. Their prolonged half-lives \u2013 257 h for dalbavancin and 195 h for oritavancin \u2013 allow for less frequent dosing. However, a long half-life also leads to prolonged drug exposure in the event of adverse effects. Here, we report the first case of DRESS syndrome in a patient treated with dalbavancin and oritavancin. <\/jats:p>","DOI":"10.1159\/000545359","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T17:02:18Z","timestamp":1743267738000},"page":"128-136","source":"Crossref","is-referenced-by-count":1,"title":["Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome following Dalbavancin and Oritavancin Administration in a Patient with Osteomyelitis"],"prefix":"10.1159","volume":"17","author":[{"given":"Jina","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily Frech","family":"Preciado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Baxter","family":"Harlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.08.013"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.02.072"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.02.073"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12501"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1086\/379015"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2122437"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy331"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S271445"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.041"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy8020070"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4909-851"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.03.006"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107165"}],"container-title":["Case Reports in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000545359","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000545359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T16:01:02Z","timestamp":1745942462000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000545359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000545359","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.28639475","asserted-by":"subject"}]},"ISSN":["1662-6567"],"issn-type":[{"type":"electronic","value":"1662-6567"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}